InvestSMART

Syntara Limited (ASX: SNT) - Announcements

Current share price for SNT : $0.024 0.001 (4.35%)+

ASX company news and announcements for Syntara Limited (SNT) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Syntara Limited (SNT) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Syntara Limited (SNT), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Syntara Limited (SNT)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$47 Change of Director's Interest Notice - HDS 14 Mar 2025 8:31AM $0.080 $0.024 fallen by 70%
$47 Half Year Report and Appendix 4D 26 Feb 2025 3:18PM $0.082 $0.024 fallen by 70.73%
$47 Notification regarding unquoted securities - SNT 25 Feb 2025 5:53PM $0.080 $0.024 fallen by 70%
$47 Change in substantial holding 25 Feb 2025 8:02AM $0.078 $0.024 fallen by 69.23%
$47 Section 708A(5)(e) notice 20 Feb 2025 9:40AM $0.087 $0.024 fallen by 72.41%
$47 Application for quotation of securities - SNT 20 Feb 2025 9:33AM $0.087 $0.024 fallen by 72.41%
$47 SNT drug leads to significant normalisation of skin scarring 18 Feb 2025 9:55AM $0.071 $0.024 fallen by 66.20%
$47 Results of Meeting 17 Feb 2025 10:37AM $0.071 $0.024 fallen by 66.20%
$47 Chair's Address to Shareholders 17 Feb 2025 8:45AM $0.071 $0.024 fallen by 66.20%
$47 Company Secretary Appointment/Resignation 6 Feb 2025 6:05PM $0.078 $0.024 fallen by 69.23%
$47 Investor Presentation Euroz Hartleys Healthcare Forum 4 Feb 2025 10:04AM $0.065 $0.024 fallen by 63.08%
$47 Quarterly Shareholder Report 29 Jan 2025 8:53AM $0.066 $0.024 fallen by 63.64%
$47 Quarterly Appendix 4C Cash Flow Report 29 Jan 2025 8:41AM $0.066 $0.024 fallen by 63.64%
$47 Application for quotation of securities - SNT 22 Jan 2025 8:28AM $0.073 $0.024 fallen by 67.12%
$47 Notice of General Meeting/Proxy Form 17 Jan 2025 10:09AM $0.075 $0.024 fallen by 68%
$47 Change in substantial holding 23 Dec 2024 3:45PM $0.062 $0.024 fallen by 61.29%
$47 Section 708A(5)(e) notice 19 Dec 2024 9:17AM $0.062 $0.024 fallen by 61.29%
$47 Application for quotation of securities - SNT 19 Dec 2024 9:12AM $0.062 $0.024 fallen by 61.29%
$47 Proposed issue of securities - SNT 12 Dec 2024 10:24AM $0.062 $0.024 fallen by 61.29%
$47 Proposed issue of securities - SNT 12 Dec 2024 10:00AM $0.067 $0.024 fallen by 64.18%
$47 Equity Raising Presentation 12 Dec 2024 10:00AM $0.067 $0.024 fallen by 64.18%
$47 Placement 12 Dec 2024 10:00AM $0.067 $0.024 fallen by 64.18%
$47 Presentation: Phase 2 study of SNT-5505 in myelofibrosis 10 Dec 2024 12:31PM $0.067 $0.024 fallen by 64.18%
$47 Interim data in Phase 2 study of SNT-5505 in myelofibrosis 10 Dec 2024 12:31PM $0.067 $0.024 fallen by 64.18%
$47 Notice of SNT-5505 Interim Phase 2 data webinar 10 Dec 2024 10:18AM $0.067 $0.024 fallen by 64.18%

126 - 150 of 267 results

Page 6 of 11

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.